Albireo Pharma, Inc. (NASDAQ: ALBO) a clinical-stage company targeting rare liver diseases, announced the acceptance of its New Drug Application (NDA) for odevixibat, a once-daily, non-systemic IBAT, intended for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The candidate is also...
Menlo Therapeutics (NASDAQ: MNLO), a late-stage biopharmaceutical company, has announced the completion of enrollment of patients in a crucial phase 2 clinical trial for studying the efficacy and safety of once daily oral serlopitant for the treatment of Chronic Pruritus (itch) of Unknown Origin (CPUO)....
Cara Therapeutics (NASDAQ: CARA) recently posted its first quarter, 2019 results. The company reported a net loss of $22.0 million, or $0.56 per basic and diluted share compared to a net loss of $16.8 million, or $0.51 per basic and diluted share, for the first...
Pruritus is characterized by an uncomfortable and persistent urge to scratch caused either due to a skin disorder or an underlying systemic disease such as atopic dermatitis, mycoses, chickenpox, hepatitis, Jaundice, chronic renal failure, cholestasis or NASH. These can be chronic in nature and affect...
